Evidence Repository
The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!

Variant: NM_000546.6(TP53):c.836G>A (p.Gly279Glu)

CA16620616

419454 (ClinVar)

Gene: TP53 (HGNC:7157)
Condition: Li-Fraumeni syndrome (MONDO:0018875)
Inheritance Mode: Autosomal dominant inheritance
UUID: 68394e7b-9085-44a7-8d34-8eb830aa2554
Approved on: 2026-06-04
Published on: 2026-09-22

HGVS expressions

NM_000546.6(TP53):c.836G>A (p.Gly279Glu)
NM_000546.6:c.836G>A
NC_000017.11:g.7673784C>T
CM000679.2:g.7673784C>T
NC_000017.10:g.7577102C>T
CM000679.1:g.7577102C>T
NC_000017.9:g.7517827C>T
NG_017013.2:g.18767G>A
ENST00000503591.2:c.836G>A
ENST00000508793.6:c.836G>A
ENST00000509690.6:c.440G>A
ENST00000514944.6:c.557G>A
ENST00000604348.6:c.815G>A
ENST00000269305.9:c.836G>A
ENST00000269305.8:c.836G>A
ENST00000359597.8:c.836G>A
ENST00000413465.6:c.782+397G>A
ENST00000420246.6:c.836G>A
ENST00000445888.6:c.836G>A
ENST00000455263.6:c.836G>A
ENST00000504290.5:c.440G>A
ENST00000504937.5:c.440G>A
ENST00000509690.5:c.440G>A
ENST00000510385.5:c.440G>A
ENST00000610292.4:c.719G>A
ENST00000610538.4:c.719G>A
ENST00000610623.4:c.359G>A
ENST00000615910.4:c.803G>A
ENST00000617185.4:c.836G>A
ENST00000618944.4:c.359G>A
ENST00000619186.4:c.359G>A
ENST00000619485.4:c.719G>A
ENST00000620739.4:c.719G>A
ENST00000622645.4:c.719G>A
ENST00000635293.1:c.719G>A
NM_000546.5:c.836G>A
NM_001126112.2:c.836G>A
NM_001126113.2:c.836G>A
NM_001126114.2:c.836G>A
NM_001126115.1:c.440G>A
NM_001126116.1:c.440G>A
NM_001126117.1:c.440G>A
NM_001126118.1:c.719G>A
NM_001276695.1:c.719G>A
NM_001276696.1:c.719G>A
NM_001276697.1:c.359G>A
NM_001276698.1:c.359G>A
NM_001276699.1:c.359G>A
NM_001276760.1:c.719G>A
NM_001276761.1:c.719G>A
NM_001276695.2:c.719G>A
NM_001276696.2:c.719G>A
NM_001276697.2:c.359G>A
NM_001276698.2:c.359G>A
NM_001276699.2:c.359G>A
NM_001276760.2:c.719G>A
NM_001276761.2:c.719G>A
NM_001126112.3:c.836G>A
NM_001126113.3:c.836G>A
NM_001126114.3:c.836G>A
NM_001126115.2:c.440G>A
NM_001126116.2:c.440G>A
NM_001126117.2:c.440G>A
NM_001126118.2:c.719G>A
NM_001276695.3:c.719G>A
NM_001276696.3:c.719G>A
NM_001276697.3:c.359G>A
NM_001276698.3:c.359G>A
NM_001276699.3:c.359G>A
NM_001276760.3:c.719G>A
NM_001276761.3:c.719G>A
More

Pathogenic

Met criteria codes 7
PS3 PM1 PM2_Supporting PS2_Moderate PP4_Moderate PS4_Moderate PP3_Moderate
Not Met criteria codes 11
PS1 PM4 BA1 PP2 PVS1 BS3 BS1 BP3 BP4 BP1 BP7

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for TP53 Version 2.4

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
TP53 VCEP
The NM_000546.6: c.836G>A variant in TP53 is a missense variant predicted to cause substitution of glycine by glutamic acid at amino acid 279 (p.Gly279Glu). This variant has been identified as a de novo occurrence with unconfirmed parental relationships in 1 individual with a strongly LFS-associated cancer totaling 2 phenotype points (PS2_Moderate; Internal lab contributor). This variant has been reported in 4 unrelated families meeting 2015 Revised Chompret testing criteria. Based on this evidence, this variant scores 2 total points meeting the TP53 VCEP phenotype scoring criteria of 2-3.5 points. (PS4_Moderate; Internal lab contributors). At least two individuals with this variant were found to have a variant allele fraction of 5-25%, which is a significant predictor of variant pathogenicity (PP4_Moderate, PMID: 34906512, Internal lab contributors). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity by the majority of available assays indicating that this variant impacts protein function (PS3; PMIDs: 12826609, 30224644, 29979965, 39774325). Computational predictor scores (BayesDel = 0.6431; Align GVGD = Class 65) are above recommended thresholds (BayesDel > 0.16 and an Align GVGD Class of 65), evidence that correlates with impact to TP53 via protein change (PP3_Moderate). This variant has 26 somatic occurrences for the same amino acid change in cancerhotspots.org (v2) sufficient to be defined as a mutational hotspot by the Clingen TP53 VCEP (≥ 10 somatic occurrences, PMID: 30311369) (PM1). In summary, this variant meets the criteria to be classified as pathogenic for Li Fraumeni syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: PS2_Moderate, PS4_Moderate, PS3, PP3_Moderate, PP4_Moderate, PM1, PM2_Supporting. (Bayesian Points: 15; VCEP specifications version 2.4).
Met criteria codes
PS3
In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity by the majority of available assays indicating that this variant impacts protein function (PS3; PMIDs: 12826609, 30224644, 29979965, 39774325).
PM1
This variant has 26 somatic occurrences for the same amino acid change in cancerhotspots.org (v2) sufficient to be defined as a mutational hotspot by the Clingen TP53 VCEP (≥ 10 somatic occurrences, PMID: 30311369) (PM1).
PM2_Supporting
This variant is absent from gnomAD v4.1.0 (PM2_Supporting).
PS2_Moderate
This variant has been identified as a de novo occurrence with unconfirmed parental relationships in 1 individual with a strongly LFS-associated cancer totaling 2 phenotype points (PS2_Moderate; Internal lab contributor).
PP4_Moderate
At least two individuals with this variant were found to have a variant allele fraction of 5-25%, which is a significant predictor of variant pathogenicity (PP4_Moderate, PMID: 34906512, Internal lab contributors).
PS4_Moderate
This variant has been reported in 4 unrelated families meeting 2015 Revised Chompret testing criteria. Based on this evidence, this variant scores 2 total points meeting the TP53 VCEP phenotype scoring criteria of 2-3.5 points. (PS4_Moderate; Internal lab contributors).
PP3_Moderate
Computational predictor scores (BayesDel = 0.6431; Align GVGD = Class 65) are above recommended thresholds (BayesDel > 0.16 and an Align GVGD Class of 65), evidence that correlates with impact to TP53 via protein change (PP3_Moderate).
Not Met criteria codes
PS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PVS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP7
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
ClinGen Terms of Use.
¤ Powered by BCM's Genboree.